TARBELA-PDNCT07781644
Study to Test Effects and Safety of RO7568282 in Early Parkinson's Disease
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 5 versions: 5 with changes below. See every version on ClinicalTrials.gov ↗
- Minor Start date changed from estimate of Nov 10, 2026 to Nov 11, 2026
- Study sites: 4 to 6
- Notable Phase changed: Phase 1/2 → Phase 2
- Recruitment opened
- Start date pushed from Sep 30, 2026 to Nov 10, 2026
- Trial sites expanded: 0 → 4 locations
- Minor Study sites: 0 to 2
- Notable Eligibility criteria expanded, about 12 words
- Secondary endpoints: details revised at 1 of 5 entries
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Time to a Confirmed Motor Progression Event From the Randomization Date, as Measured by the MDS-UPDRS Part III Score
Timeframe: Up to at least Week 104
Secondary (5)
Change in Motor Signs From Baseline at Week 104, as Measured by the MDS-UPDRS Part III Score
Time to Worsening of Participants' Motor Function, as Reported by the Participant in the Presence of a Confirmed Motor Progression Event
Incidence of Adverse Events (AEs)
Change From Baseline in Columbia-suicide Severity Rating Scale (C-SSRS)
Plasma Concentrations of RO7568282
Arms and interventions
RO7568282 High DoseExperimental
RO7568282 will be administered as per the schedule specified in the protocol.
RO7568282 Low DoseExperimental
RO7568282 will be administered as per the schedule specified in the protocol.
PlaceboPlacebo comparator
Placebo will be administered as per the schedule specified in the protocol.
Drugs: RO7568282, Placebo
Sites
6 sites in 5 countries
United Kingdom 2, China 1, Ireland 1, Poland 1, United States 1